This is also considered one of the main factors that promote obesity, diabetes and neuropsychiatric disorders (55)
Industry market reports project the Alzheimers market to grow from $4.8 billion to $8.18 billion by 2032 and MASH/NASH to grow from $1.62 to $24.2 billion by 2028
Moving forward, the results of the phase 3 SURPASS clinical trial program demonstrated that tirzepatide was as effective and safe as other anti-diabetic agents, such as semaglutide and dulaglutide (SURPASS-2) (SURPASS J-mono), long-acting insulin analogs (degludec and glargine) (SURPASS-3,4), and placebo (SURPASS-1) (SURPASS-5), in managing T2DM diabetes [65,66,67,68,69]
By addressing multiple metabolic dysfunction pathways simultaneously, retatrutides triple agonism offers a promising new horizon in obesity and diabetes treatment